Skip to main content

Table 1 Association analysis of rs2231142, rs10011796 (ABCG2) and rs11942223 (SLC2A9) in European and NZ Polynesian sample sets

From: Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout

SNP Raw N Genotype, N (%) Effect allele, N (%) Gout vs. HU*^
OR (95% CI), P
Gout vs. All Controls*
OR (95% CI), P
HU vs. NU*
OR, 95% CI, P
rs2231142   GG GT TT T    
European gout 1637 1006 (61.5) 551 (33.7) 80 (7.5) 711 (21.7) 1.81 (1.60–2.06), 3.0E−20
1.85 (1.63–2.11), 3.8E−21
2.42 (2.18–2.68), 1.9E−64
European HU 2378 1762 (74.1) 577 (24.3) 39 (1.6) 655 (13.8) 1.56 (1.41–1.72), 1.7E−18
European NU 11,604 9428 (81.2) 2053 (17.7) 123 (1.1) 2299 (9.1)  
WP# gout 369 96 (26.0) 189 (51.2) 84 (22.8) 357 (48.4) 1.96 (1.30–3.00), 1.6E−03
1.77 (1.14–2.80), 0.012
2.36 (1.73–3.26), 1.1E−07
WP HU 88 48 (54.6) 29 (33.0) 11 (12.5) 51 (29.0) 1.52 (0.94–2.50), 0.091
WP NU 146 84 (57.5) 52 (35.6) 10 (6.9) 72 (24.7)
EP# gout 543 436 (80.3) 106 (19.5) 1 (0.2) 108 (9.9) 1.99 (1.05–4.05), 0.044
2.02 (1.05–4.16) 0.043
2.54 (1.66–3.97), 3.4E−05
EP HU 114 101 (88.6) 13 (11.4) 0 (0.0) 13 (5.7) 1.41 (0.65–2.93), 0.37
EP NU 348 315 (90.5) 32 (9.2) 1 (0.3) 34 (4.9)  
rs10011796   CC CT TT T    
European gout 1580 339 (21.5) 764 (48.4) 477 (30.2) 1718 (54.4) 1.39 (1.26–1.53), 2.0E−11
1.39 (1.26–1.53), 3.5E−11
1.55 (1.44–1.69), 1.3E−27
European HU 2422 666 (27.5) 1208 (49.9) 548 (22.6) 2304 (47.6) 1.18 (1.10–1.26), 7.8E−07
European NU 11,927 3688 (30.9) 5986 (50.2) 2253 (18.9) 10,492 (44.0)  
WP gout 369 38 (10.3) 163 (44.2) 168 (45.5) 499 (67.6) 1.28 (0.86–1.91), 0.22
1.27 (0.83–1.94), 0.27
1.32 (0.99–1.77), 0.062
WP HU 88 10 (11.4) 43 (48.9) 35 (39.8) 113 (64.2) 1.02 (0.66–1.60), 0.92
WP NU 146 21 (14.4) 67 (45.9) 58 (39.3) 183 (62.7)  
EP gout 543 93 (17.2) 259 (47.9) 189 (34.9) 637 (58.9) 0.94 (0.68–1.29), 0.69
0.92 (0.66–1.27), 0.60
1.03 (0.83–1.27), 0.80
EP HU 114 18 (15.8) 51 (44.7) 45 (39.5) 141 (61.8) 1.13 (0.81–1.57), 0.48
EP NU 348 67 (19.3) 173 (49.7) 108 (31.0) 389 (55.9)  
rs11942223   TT TC CC C    
European gout 1576 1168 (74.1) 382 (24.2) 26 (1.6) 434 (13.8) 0.72 (0.63–0.83), 2.9E−06
0.73 (0.63–0.83), 4.7E−06
0.55 (0.49–0.62), 1.4E−25
European HU 2422 1658 (68.5) 701 (28.9) 63 (2.6) 827 (17.1) 0.66 (0.61–0.73), 2.2E−21
European NU 11,927 7101 (59.5) 4220 (35.4) 606 (5.1) 5432 (22.8)  
WP gout 369 351 (95.1) 18 (4.9) 0 (0.0) 18 (2.4) 0.53 (0.17–2.05), 0.31
0.51 (0.15–2.08), 0.31
0.61 (0.26–1.46), 0.26
WP HU 88 84 (95.5) 4 (4.6) 0 (0.0) 4 (2.3) 0.83 (0.20–2.94), 0.78
WP NU 146 135 (92.5) 11 (7.5) 0 (0.0) 11 (3.8)  
EP gout 543 501 (92.3) 39 (7.2) 3 (0.6) 45 (4.1) 1.04 (0.47–2.61), 0.92
1.24 (0.54–3.23), 0.64
1.06 (0.62–1.84), 0.84
EP HU 114 105 (92.1) 9 (7.9) 0 (0.0) 9 (3.9) 1.26 (0.51–12.94), 0.60
EP NU 348 311 (89.4) 37 (10.6) 0 (0.0) 37 (5.3)  
  1. *European sample set adjusted by age and sex. Polynesian sample sets additionally adjusted by PCs 1–10
  2. ^For Gout vs. HU analyses, the top data is before adjustment by highest recorded serum urate, and the bottom figure is after adjustment
  3. All sample sets are in Hardy-Weinberg equilibrium (P > 0.01)
  4. Polynesian meta-analysis of WP and EP Gout vs. HU, and of HU vs. NU yielded ORmeta = 1.85, P = 1.3E03., and ORmeta = 1.49, P = 0.057, respectively
  5. #WP Western Polynesian, EP Eastern Polynesian